Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.
Long-acting growth hormone (LAGH) preparations are currently being developed in an attempt to improve adherence. The profile of growth hormone (GH) action following administration of LAGH raises practical questions about clinical monitoring, and long-term safety and efficacy of these new therapeutic agents. Recent literature and meeting proceedings regarding LAGH preparations are reviewed. Multiple LAGH preparations are currently at various stages of development allowing for decreased GH injection frequency from daily to weekly, bi-weekly, or monthly. Following administration of LAGH, the serum peak and trough GH and IGF-I levels vary depending upon the mechanism used to prolong GH action. Randomized, controlled clinical trials of some LAGH preparations have reported non-inferiority compared to daily recombinant human GH (rhGH) for improved growth velocity and body composition in children and adults with GH deficiency (GHD), respectively. No significant LAGH-related adverse events have been reported during short-term therapy. Multiple LAGH preparations are proceeding through clinical development with some showing promising evidence of short-term clinical efficacy and safety in children and adults with GHD.The relationship of transient elevations of GH and IGF-I following administration of LAGH to efficacy and safety remain to be elucidated. In order for LAGH to replace daily rhGH in the treatment of individuals with GHD, a number of practical questions need to be addressed including methods of dose adjustment, timing of monitoring of IGF-I, safety, efficacy and cost-effectiveness. Long-term surveillance of efficacy and safety of LAGH preparations will be needed to answer these clinically relevant questions.